
What smart money is saying about CSL Limited
2 funds in our archive have pitched CSL Limited — most recently Brown Advisory Global Value Select Strategy in June 2026.
CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Fund coverage · 2 theses
- Brown Advisory Global Value Select StrategyJune 2026
CSL Limited is a high-quality biopharma business with attractive economics now available at a low multiple.
Read the full thesis - Cooper Investors Endowment FundDecember 2024
CSL Ltd is a company with a strong growth outlook despite recent setbacks in its clinical pipeline, driven by robust product offerings and a shift in management focus toward capital returns.
Read the full thesis
Read every full thesis on CSL Limited
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→